Evidence map›Paper›PMID 36684426›Full record

ArticleFrontiers in cell and developmental biology2022

Differentiation of human induced pluripotent stem cells into cortical neural stem cells.

Alexandra Neaverson, Malin H L Andersson, Osama A Arshad, Luke Foulser, Mary Goodwin-Trotman, Adam Hunter, Ben Newman, Minal Patel, Charlotte Roth, Tristan Thwaites and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Stem cells in organogenesis and regeneration.Stem cell research & therapy · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Alexandra NeaversonWellcome Sanger Institute, Cambridge, United Kingdom.
Malin H L AnderssonWellcome Sanger Institute, Cambridge, United Kingdom.
Osama A ArshadWellcome Sanger Institute, Cambridge, United Kingdom.
Luke FoulserWellcome Sanger Institute, Cambridge, United Kingdom.
Mary Goodwin-TrotmanWellcome Sanger Institute, Cambridge, United Kingdom.
Adam HunterWellcome Sanger Institute, Cambridge, United Kingdom.
Ben NewmanWellcome Sanger Institute, Cambridge, United Kingdom.
Minal PatelWellcome Sanger Institute, Cambridge, United Kingdom.
Charlotte RothUCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
Tristan ThwaitesWellcome Sanger Institute, Cambridge, United Kingdom.
Helena KilpinenWellcome Sanger Institute, Cambridge, United Kingdom.
Matthew E HurlesWellcome Sanger Institute, Cambridge, United Kingdom.
Andrew DayWellcome Sanger Institute, Cambridge, United Kingdom.
Sebastian S GeretyWellcome Sanger Institute, Cambridge, United Kingdom.
Wellcome Sanger Institute · GBOpen Targets · GBUniversity College London · GB

Funding

Medical Research Council MR/L016311/1Wellcome Trust
6 · The paper itself

Abstract

Efficient and effective methods for converting human induced pluripotent stem cells into differentiated derivatives are critical for performing robust, large-scale studies of development and disease modelling, and for providing a source of cells for regenerative medicine. Here, we describe a 14-day neural differentiation protocol which allows for the scalable, simultaneous differentiation of multiple iPSC lines into cortical neural stem cells We currently employ this protocol to differentiate and compare sets of engineered iPSC lines carrying loss of function alleles in developmental disorder associated genes, alongside isogenic wildtype controls. Using RNA sequencing (RNA-Seq), we can examine the changes in gene expression brought about by each disease gene knockout, to determine its impact on neural development and explore mechanisms of disease. The 10-day Neural Induction period uses the well established dual-SMAD inhibition approach combined with Wnt/β-Catenin inhibition to selectively induce formation of cortical NSCs. This is followed by a 4-day Neural Maintenance period facilitating NSC expansion and rosette formation, and NSC cryopreservation. We also describe methods for thawing and passaging the cryopreserved NSCs, which are useful in confirming their viability for further culture. Routine implementation of immunocytochemistry Quality Control confirms the presence of PAX6-positive and/or FOXG1-positive NSCs and the absence of OCT4-positive iPSCs after differentiation. RNA-Seq, flow cytometry, immunocytochemistry (ICC) and RT-qPCR provide additional confirmation of robust presence of NSC markers in the differentiated cells. The broader utility and application of our protocol is demonstrated by the successful differentiation of wildtype iPSC lines from five additional independent donors. This paper thereby describes an efficient method for the production of large numbers of high purity cortical NSCs, which are widely applicable for downstream research into developmental mechanisms, further differentiation into postmitotic cortical neurons, or other applications such as large-scale drug screening experiments.

Indexed as

developmental disordersin vitro disease modellingIPSCneural differentiationneural stem cellprotocolRNA-seq

Identifiers

PMID36684426
PMCPMC9849742
OpenAlexW4313560229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.